Lantheus Holdings, Inc.

Background

Company Name	Lantheus Holdings, Inc.
Stock Symbol	LNTH
Class Period	February 26, 2025 to August 05, 2025
Lead Plaintiff Motion Deadline	November 10, 2025

Submit Your Information

If you suffered a loss on your Lantheus Holdings, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before February 26, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On May 7, 2025, Lantheus released its first quarter 2025 financial results, missing consensus estimates, specifically with the Company’s key Radiopharmaceutical Oncology product, Pylarify. The Company disclosed that Pylarify sales had decreased year-over-year due to an alleged “temporal competitive disruption.” Additionally, the Company reduced its full-year guidance.

On this news, Lantheus’s stock price fell $24.35, or 23.2%, to close at $80.49 per share on May 7, 2025, thereby injuring investors.

Then, on August 6, 2025, Lantheus released its second quarter 2025 financial results, once again missing estimates and significantly reduced growth expectations for Pylarify, due to ongoing completion impacting pricing dynamics. The Company further slashed its full-year guidance.

On this news, Lantheus’s stock price fell $20.76, or 28.6%, to close at $51.87 per share on August 6, 2025, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Lantheus did not have an accurate understanding of the pricing and competitive dynamics of Pylarify’s market; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information